Voyager Therapeutics Debt to Equity Ratio 2014-2022 | VYGR
Current and historical debt to equity ratio values for Voyager Therapeutics (VYGR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Voyager Therapeutics debt/equity for the three months ending March 31, 2022 was 0.00.
| Voyager Therapeutics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-03-31 |
$0.15B |
$0.08B |
1.95 |
| 2021-12-31 |
$0.10B |
$0.10B |
1.04 |
| 2021-09-30 |
$0.10B |
$0.09B |
1.11 |
| 2021-06-30 |
$0.10B |
$0.11B |
0.89 |
| 2021-03-31 |
$0.10B |
$0.14B |
0.75 |
| 2020-12-31 |
$0.11B |
$0.15B |
0.70 |
| 2020-09-30 |
$0.10B |
$0.17B |
0.62 |
| 2020-06-30 |
$0.22B |
$0.08B |
2.87 |
| 2020-03-31 |
$0.24B |
$0.08B |
3.05 |
| 2019-12-31 |
$0.26B |
$0.10B |
2.57 |
| 2019-09-30 |
$0.27B |
$0.11B |
2.48 |
| 2019-06-30 |
$0.27B |
$0.12B |
2.28 |
| 2019-03-31 |
$0.31B |
$0.10B |
3.09 |
| 2018-12-31 |
$0.13B |
$0.05B |
2.81 |
| 2018-09-30 |
$0.13B |
$0.07B |
2.01 |
| 2018-06-30 |
$0.13B |
$0.08B |
1.62 |
| 2018-03-31 |
$0.14B |
$0.10B |
1.39 |
| 2017-12-31 |
$0.05B |
$0.13B |
0.38 |
| 2017-09-30 |
$0.06B |
$0.09B |
0.65 |
| 2017-06-30 |
$0.05B |
$0.11B |
0.51 |
| 2017-03-31 |
$0.05B |
$0.12B |
0.43 |
| 2016-12-31 |
$0.05B |
$0.14B |
0.40 |
| 2016-09-30 |
$0.05B |
$0.15B |
0.35 |
| 2016-06-30 |
$0.05B |
$0.16B |
0.35 |
| 2016-03-31 |
$0.06B |
$0.16B |
0.35 |
| 2015-12-31 |
$0.06B |
$0.17B |
0.36 |
| 2015-09-30 |
$0.07B |
$0.10B |
0.64 |
| 2015-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2014-12-31 |
$0.01B |
$0.00B |
9.01 |
| 2014-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$-0.00B |
-1.04 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.227B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
